Acasti Pharma Inc.
ACST
$2.69
-$0.21-7.24%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 64.89% | 60.40% | 32.51% | 25.76% | -49.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.87% | -11.90% | 19.97% | 50.25% | 18.14% |
| Operating Income | 19.87% | 11.90% | -19.97% | -50.25% | -19.20% |
| Income Before Tax | -161.72% | -175.86% | -325.23% | -396.52% | -60.58% |
| Income Tax Expenses | -644.05% | -845.45% | -977.42% | -1,372.53% | -- |
| Earnings from Continuing Operations | -124.83% | -135.03% | -273.52% | -332.11% | -49.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -124.83% | -135.03% | -273.52% | -332.11% | -49.17% |
| EBIT | 19.87% | 11.90% | -19.97% | -50.25% | -19.20% |
| EBITDA | 17.50% | 7.96% | -27.38% | -60.50% | -22.22% |
| EPS Basic | -137.34% | -153.45% | -338.54% | -310.15% | 14.28% |
| Normalized Basic EPS | 18.41% | -2.42% | -104.09% | -114.47% | 14.67% |
| EPS Diluted | -137.34% | -153.45% | -338.54% | -309.62% | 14.34% |
| Normalized Diluted EPS | 18.41% | -2.42% | -104.09% | -114.47% | 14.67% |
| Average Basic Shares Outstanding | 0.21% | -11.65% | -6.62% | 3.07% | 60.66% |
| Average Diluted Shares Outstanding | 0.21% | -11.65% | -6.62% | 3.07% | 60.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
